Document:

<PAGE>   1

                                                                   EXHIBIT 10.29

                               SECOND ADDENDUM TO
                        LICENSE AND DEVELOPMENT AGREEMENT
                         FOR SPECIFIC MEDICAL TECHNOLOGY
                    FOR THE DETECTION OF ONCOGENIC HPV VIRUS

         This is a Second Addendum to the License and Development Agreement for
Specific Medical Technology for the Detection of Oncogenic HPV Virus dated June
23, 2000 ("License and Development Agreement") by and between INVIRION, a United
States corporation organized and existing under the laws of the State of
Illinois, having a place of business at 2350 Pilgrim Highway, Frankfort,
Michigan 49635 ("Invirion") and AMPERSAND MEDICAL CORPORATION, a Delaware
corporation, having a place of business at 414 North Orleans, Chicago, Illinois
60610 ("Ampersand").

         Except to the extent modified by this Second Addendum, the License and
Development Agreement and related First Addendum are hereby reaffirmed.

         The License and Development Agreement is hereby modified by
incorporating into it the following agreement between the parties:

         1. Effective as of June 23, 2000 the License and Development Agreement
for Specific Medical Technology for the Detection of Oncogenic HPV Virus shall
be between Bruce Patterson, an individual inventor residing in Chicago, Illinois
(hereinafter "Patterson") and Ampersand. All payments previously made to
Invirion and all warrants issued to Invirion shall be considered by the parties
as having been received by Patterson, and are hereby acknowledged by Patterson.
Ampersand shall take whatever steps are necessary to change the warrants to
reflect the above.

         2. As a result of Patterson meeting the benchmarks set forth in
Paragraphs 3.1(1), 3.1(2), and 3.1(3), the parties now agree that the following
payment terms will be used to pay Patterson for the balance owed by Ampersand as
set froth in Paragraph 3.1:

                                        1
<PAGE>   2

            Starting on January 11, 2001 Ampersand will pay Patterson
            $50,000 per month for a period of six months for a total of
            $300,000.

         3. In the event the License and Development Agreement is terminated,
all payments made and owed to Patterson and all warrants issued to Patterson are
non-refundable and all warrants are irrevocable and non-cancellable. Ampersand
acknowledges that all payments made and owed as well as the issuance of warrants
to Patterson are for services already performed by Patterson prior to such
payment or issuance of the warrant.

         IN WITNESS WHEREOF, the parties hereto have caused to be signed, by
their duly authorized officers, this Second Addendum of the License and
Development Agreement originally dated June 23, 2000, on the dates set
forth below.

BRUCE PATTERSON

_____________________________________

DATED:_______________________________

AMPERSAND MEDICAL CORPORATION

BY:__________________________________

DATED: ______________________________

                                       2<PAGE>   1
                                                                   EXHIBIT 10.30

                                 PROMISSORY NOTE

PRINCIPAL $25,000.                                        DATE: FEBRUARY 1, 2001
2000

     1. PRINCIPAL AND INTEREST. Ampersand Medical Corporation, a corporation
organized and existing under the laws of the State of Delaware (the "Company"),
with offices at 414 N. Orleans St., Suite 510, Chicago, Illinois, 60610 for
value received, hereby promises to pay to the order of Azimuth Corporation (the
"Holder"), with offices at 3600 Rio Vista Avenue, Suite A, Orlando, Florida
32805, or any successor in interest in lawful money of the United States at the
address of the Holder set forth below, the principal sum of Twenty-Five Thousand
and 00/100 Dollars ($25,000) 30 days from date of issue (the "Maturity Date"),
together with simple interest from the date hereof, computed on the basis of a
365-day year from the date of original issuance until the Maturity Date, or such
earlier payment date as described below, at the rate of 15% per annum.

     2. PREPAYMENT. The principal amount of the Note, plus any accrued interest
due thereon, may be prepaid in its entirety at any time. The holder shall have
the option of offsetting the principal, and any accrued interest due thereon
against any monies paid to Ampersand in accordance with the terms of the
Holder's subscription evidencing participation in a Confidential Private
Offering of shares of Series B Convertible Preferred Stock.

     3. DEFAULT PENALTY PROVISIONS. If the Company fails to pay the principal
and accrued interest due thereon on the maturity date, interest shall continue
to accrue as computed above at an adjusted rate of 18% per annum from the
Maturity Date until the date the note and accrued interest is paid in full.

     4. USE OF PROCEEDS. General corporate purposes.

     5. GOVERNING LAW. The Note is delivered in and shall be construed in
accordance with the laws of the State of Illinois, without regard to conflicts
of laws provisions thereof.

        IN WITNESS WHEREOF, and intending to be legally bound hereby, the
Company has caused this Note to be executed and delivered by its proper and duly
authorized officers as of the date first above written.

AMPERSAND MEDICAL CORPORATION

BY:________________________________

NAME:  LEONARD R. PRANGE
TITLE: PRESIDENT, COO/CFO<PAGE>   1

                                                                   EXHIBIT 10.31
                                 PROMISSORY NOTE

PRINCIPAL $470,000.                                 ISSUE DATE: FEBRUARY 7, 2001

     1. PRINCIPAL AND INTEREST. Ampersand Medical Corporation, a corporation
organized and existing under the laws of the State of Delaware (the "Company"),
with offices at 414 N. Orleans St., Suite 510, Chicago, Illinois, 60610 for
value received, hereby promises to pay to the order of Azimuth Corporation (the
"Holder"), with offices at 3600 Rio Vista Avenue, Suite A, Orlando, Florida
32805, or any successor in interest, in lawful money of the United States at the
address of the Holder set forth above, the principal sum of Four Hundred and
Seventy Thousand and 00/100 Dollars ($470,000) 180 days from issue date or such
earlier date as hereinafter provided (the "Maturity Date"), together with simple
interest from the issue date above identified (the "Issue Date"), computed on
the basis of actual days elapsed from such date until the Maturity Date, or such
earlier payment date as described below, at the rate of 15% per annum.

     2. PREPAYMENT. The principal amount of this Note, plus any accrued interest
due thereon, may be prepaid in its entirety at any time.

     3. ADDITIONAL CONSIDERATION. The Company will issue a warrant in form and
substance acceptable to the Holder, within fifteen (15) days after the Issue
Date, entitling the Holder to purchase 1,000,000 shares of Common Stock of the
Company at an exercise price of $0.25 per share. If such warrant is not issued
within such 15-day period, the principal amount of this Note plus any accrued
interest thereon shall be immediately due and payable in its entirety. The
Company will grant registration rights covering such shares of Common Stock, as
well as the (i) 506,250 shares of Common Stock issued to the Holder in 1999,
(ii) 50,000 shares of Common Stock (subject to adjustment) issuable upon
exercise of the warrant dated December 10, 1999 issued by the Company to the
Holder, (iii) 50,000 shares of Common Stock (subject to adjustment) issuable
upon exercise of the warrant dated December 1, 2000 issued by the Company to the
Holder, (iv) 1,000,000 shares of Common Stock (subject to adjustment) issuable
upon exercise of the warrant dated December 8, 2000 issued by the Company to the
Holder, and (v) 500,000 shares of Common Stock (subject to adjustment) issuable
upon conversion of the $500,000 principal amount promissory note dated September
22, 2000 issued by the Company to the Holder, in each case, within thirty (30)
days after the Issue Date. Such registration rights will be in form and
substance acceptable to the Holder. If such rights are not granted within such
30-day period, the principal amount of this Note plus any accrued interest
thereon shall be immediately due and payable in its entirety.

     4. DEFAULT PENALTY PROVISIONS. If the Company fails to pay the principal of
this Note and accrued interest due thereon on the Maturity Date, interest shall
continue to accrue as computed above at an adjusted rate of 18% per annum from
the Maturity Date until the date this Note and such accrued interest is paid in
full.

     5. RECLASSIFICATION, ETC. If the Company at any time shall, by subdivision,
combination or reclassification of securities or otherwise, change any of the
securities into which the aforementioned warrant is exercisable into the same or
a different number of securities of any class or classes of securities of the
Company, or exchange any such securities in a merger or acquisition for
securities or property of another company, the Holder shall be entitled to the
same rights in such new securities or property as the Holder would have been
entitled to if immediately prior to such change the Holder had acquired shares
of Common Stock into which such warrant is exercisable.

     6. USE OF PROCEEDS. The proceeds of this Note shall be used, together with
$30,000 previously advanced by Holder to the Company, to fund a loan totaling
$500,000 to AccuMed International, Inc., required in accordance with the terms
of a definitive agreement of the Company to acquire 100% of AccuMed. The Company
shall apply $800,000 of the proceeds of any debt or equity financing consummated
after the date hereof to prepay the principal amount and accrued interest due on
such indebtedness of the Company held by the Holder (including this Note) as
shall be selected at the time by the Holder.

<PAGE>   2

     7. GOVERNING LAW. The Note is delivered in and shall be construed in
accordance with the laws of the State of Illinois, without regard to conflicts
of laws provisions thereof.

        IN WITNESS WHEREOF, and intending to be legally bound hereby, the
Company has caused this Note to be executed and delivered by its proper and duly
authorized officers as of the date first above written.

AMPERSAND MEDICAL CORPORATION

BY:________________________________

NAME:  LEONARD R. PRANGE
TITLE: PRESIDENT, COO/CFO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}]]